44th week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150306030 | Method of Liquefying Solid Form of Medication - A method of liquefying solid form of medication into a liquefied medication solution is implemented by a medication liquefaction system and a removable medicine container. The solid form medication, which is difficult to swallow by itself, and a desired amount of drinkable fluid base product are added into the removable medicine container before the removable medicine container is hermetically attached with the medication liquefaction system. Then a carbon dioxide (CO | 2015-10-29 |
20150306031 | STABLE MONTELUKAST SOLUTION - A solution that is stable at 5° C. to 30° C. for at least 24 hours, comprising: (a) water, (b) montelukast sodium; (c) a carrier material for a fast disintegrating dosage form; and (d) a component selected from a strong base, a bicarbonate salt and mixtures thereof. The solution comprising montelukast sodium is stable under conditions that are typically encountered during certain phases of the manufacturing process of fast disintegrating dosage form that contain the montelukast sodium. The solution can be used to form fast disintegrating dosage form tablets. A method of preparing a fast disintegrating dosage form tablet including preparing such solution, and forming a tablet, and a fast disintegrating dosage form that is prepared from the montelukast sodium solution are also described. | 2015-10-29 |
20150306032 | LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 2015-10-29 |
20150306033 | PHARMACEUTICAL COMPOSITION CONTAINING VITAMIN B12 - A pharmaceutical composition for intranasal administration for human subjects includes vitamin B12 and a pharmaceutically acceptable carrier. The vitamin B12 particles are dispersed in a hydrophobic continuous phase as the pharmaceutically acceptable carrier. The dispersion of solid vitamin B12 particles (crystals or amorphic) in a hydrophobic continuous phase displays very satisfactory bioavailability. Also, the intense red colour is reduced significantly, making the pharmaceutical composition acceptable for intranasal use. | 2015-10-29 |
20150306034 | FORMULATIONS AND CARRIER SYSTEMS INCLUDING COMPOUND INTERACTIVE DOMAINS - A method of creating a formulation for a compound includes determining a compound interactive agent comprising at least one group that interacts with the compound, creating a carrier agent by conjugating at least one compound interactive domain comprising the at least one group that interacts with the compound with at least one hydrophilic domain, and combining the compound and the carrier agent to create the formulation. Creating the carrier agent may further include conjugating the at least one compound interactive domain with at least one hydrophobic domain so that the at least one compound interactive domain is positioned between the at least one hydrophilic domain and the at least one hydrophobic domain. | 2015-10-29 |
20150306035 | PHARMACEUTICAL COMPOSITION CONTAINING CONVENTIONAL LIPOSOMES AND PROLONGED-CIRCULATION LIPOSOMES FOR THE TREATMENT OF VISCERAL LEISHMANIASIS - The present invention relates to a pharmaceutical composition for treating visceral leishmaniasis, characterized in that it comprises the association of conventional liposomes and prolonged-circulation liposomes with a leishmanicidal-drug delivery system. Said composition may be used in the preparation of a medicinal product for treating leishmaniasis and may be administered intramuscularly, subcutaneously, intraperitoneally or intravenously. The use of this system enables the drug efficiently to reach all sites infected by the parasite, the pegylated liposomes promoting more effective targeting of the leishmanicidal drugs on the bone marrow and spleen, whilst the conventional liposomes contribute to the targeting of the drug on the liver. | 2015-10-29 |
20150306036 | Nanoliposomal c-MYC-siRNA Inhibits In Vivo Tumor Growth of Cisplatin-Resistant Ovarian Cancer - The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA. | 2015-10-29 |
20150306037 | RELEASE OF SUBSTANCES IN SENESCENT CELLS - The invention relates to nanodevices for the controlled release of substances which comprises a support coated in oligosaccharides, wherein said oligosaccharides comprise at least 3 units of monosaccharides, and wherein at least one of the monosaccharides is galactose. These nanodevices release their load specifically in senescent cells. The invention also encompasses the method of obtainment and its uses. | 2015-10-29 |
20150306038 | A MICROPARTICLE COMPOSITION COMPRISING A PROBIOTIC, CROSS-LINKABLE REAGENT AND AN EMULSION CONTAINING A HYDROPHOBIC ACTIVE - The present invention relates to microparticles, methods of producing microparticles and microparticle precursor compositions. In particular, it relates to a method of producing a microparticle precursor composition comprising blending an emulsion comprising a hydrophobic active with a probiotic to form a probiotic-containing emulsion; and blending the probiotic-containing emulsion with a cross-linkable reagent. | 2015-10-29 |
20150306039 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS - The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as siRNA. | 2015-10-29 |
20150306040 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 2015-10-29 |
20150306041 | SUSTAINED DRUG RELEASE COMPOSITION - The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent. | 2015-10-29 |
20150306042 | BODY SURFACE TREATMENT COMPOSITION AND METHOD - A method for treating a body surface with an active agent, includes: administering a composition in a therapeutically effective amount to a body surface, the composition forming a barrier coating on the body surface that is active to sustain contact with the body surface for a duration of at least about one hour. The composition meets the following requirements: about 0.0001%2015-10-29 | |
20150306043 | COMBINATION TREATMENTS FOR BIPOLAR DISORDERS - The invention relates generally to novel compositions and methods comprising a scyllo-inositol compound and one or both of valproic acid compound and lamotrigine. The compositions and methods provide beneficial effects in the treatment of bipolar disorders. | 2015-10-29 |
20150306044 | MILD ANTIBACTERIAL CLEANSING COMPOSITIONS - Disclosed is a cleansing composition comprising: (i) a non-soap surfactant which is an alkyi glycinate, alkyi carboxy glycinate, sarcosinate, glutamate or a mixture thereof; and, (ii) one or more antimicrobial agent, wherein pH of said composition is at least 8.5 and zein number of said composition is in the range of 10 to 65 and wherein soap content of said composition is not greater than 5 wt %. The formulation is highly alkaline, yet gives mild antibacterial cleansing action. | 2015-10-29 |
20150306045 | METHOD OF REGULATING CIRCADIAN RHYTHM, AND METHOD OF PREPARING CIRCADIAN RHYTHM REGULATORY AGENT - Disclosed are a method of preparation and method of application of a circadian rhythm regulatory agent having as an active ingredient an alkylresorcinol represented by general formula (I) below and a circadian rhythm regulatory agent containing as an active ingredient an alkylresorcinol-containing extract from a cereal or a nut containing an alkylresorcinol of the following general formula (I). In the following general formula (I), R | 2015-10-29 |
20150306046 | FOODS, SYSTEMS, METHODS, AND KITS FOR PROVIDING ELECTROLYTE REPLACEMENT - Described herein are methods, compositions, systems, and kits that effectively deliver a laxative to a patient along with effective electrolyte replenishment by delivering both a laxative and electrolytes via a food item. The food item is prepared by either combining, mixing, or integrating the ingredients that form the food item together with one of or both of a laxative and electrolytes so that the ingredients in the food item either eliminate or significantly reduce the poor taste associated with either the electrolytes or the laxative. Eliminating or reducing the poor taste associated with either electrolytes or laxative, greatly improves patient satisfaction and compliance with ingesting these substances in order to, for example, prepare the GI tract of the patient for a medical or surgical procedure. | 2015-10-29 |
20150306047 | METHODS AND COMPOSITIONS FOR TREATING KIDNEY DISORDERS - The present invention provides methods for treating glomerulosclerosis such as focal segmental glomerulosclerosis (FSGS) or glomerulonephritis such as immunoglobulin A nephropathy (IgAN) by cyclohexenone compounds. | 2015-10-29 |
20150306048 | SOLUBILIZED COQ-10 - The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules. | 2015-10-29 |
20150306049 | IMMEDIATE RELEASE FORMULATIONS OF CINACALCET - The invention relates to pharmaceutical compositions comprising:
| 2015-10-29 |
20150306050 | Medications For Deposition On Biological Surfaces - Personal care compositions, such as oral medication compositions containing a flavor system comprising one or more coolants. The pleasant cool sensation provided by a coolant is enhanced in terms of quicker onset, greater intensity, impact or longer duration, which improves appeal and acceptability of the compositions to consumers. | 2015-10-29 |
20150306051 | CREATINE ORAL SUPPLEMENTATION USING CREATINE HYDROCHLORIDE SALT - The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine. | 2015-10-29 |
20150306052 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNGAL INFECTIONS - There is provided pharmaceutical compositions suitable for topical application to the nail for the treatment of nail diseases such as onychomycosis, comprising a urea-based component, a diol component, such as propylene glycol, an organic acid component, such as lactic acid, and a triol component, such a glycerol. There is further provided methods of improving the storage stability of a pharmaceutical composition suitable for topical application to the skin and/or nails comprising such urea-based components, diol components, organic acid components, and, optionally, an aqueous base, which method comprises adding a triol component, such a glycerol, to that composition prior to said storage. | 2015-10-29 |
20150306053 | THERAPEUTIC METHOD - The present invention relates generally to a method of down-regulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of down-regulating an inflammatory response in the reproductive tract or external genital tissue of a female mammal by contacting the mucosal tissue of the reproductive tract and/or genitalia with lactic acid and to agents useful for same. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response including, for example, atrophic vaginitis, irritant vaginitis or infectious vaginitis. | 2015-10-29 |
20150306054 | THE USE OF BUCILLAMINE IN THE TREATMENT OF GOUT - Disclosed are pharmaceutical compositions comprising, bucillamine, including bucillamine and allopurinol or colchicine, or pharmaceutically acceptable salts or solvates thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients. Methods for use of the said compositions in the treatment of gout and metabolic syndrome are also disclosed. | 2015-10-29 |
20150306055 | ANTIMICROBIAL COMPOSITION - An antiseptic composition suitable for use on skin and wounds comprising a source of an antimicrobial agent and an agent which disrupts biofilms. More, particularly the invention relates to a composition capable of providing effective antimicrobial activity while at the same time avoiding wound and skin irritation and retardation of wound healing. | 2015-10-29 |
20150306056 | USE OF A DHA ESTER FOR PROPHYLACTIC AND/OR CURATIVE TREATMENT OF DREPANOCYTOSIS - The present invention relates to a docosahexaenoic acid ester including an alcohol selected from among the group made up of nicotinol, panthenol, inositol, isosorbide, and isosorbide mononitrate, or one of the pharmaceutically acceptable salts, enantiomers, diastereoisomers, or mixtures thereof, including racemic mixtures, for the use thereof as a drug for the prophylactic and/or curative treatment of drepanocytosis. | 2015-10-29 |
20150306057 | METHOD FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE - The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients. | 2015-10-29 |
20150306058 | COMPOSITION COMPRISING A SINGLE VARIABLE DOMAIN AND CAMOSTAT MESYLATE (CM) - The present disclosure provides a means of stabilising a single variable domain, in particular in protease-rich environments such as the stomach and intestine. A composition, in particular a pharmaceutical composition, comprising a single variable domain and camostat mesylate is provided, together with uses of said composition as a medicament and in methods of treatment. Compositions of the disclosure are particularly useful in the topical treatment of gastrointestinal conditions, such as Crohn's Disease or ulcerative colitis, or for direct activity in the gut mucosal immune system. | 2015-10-29 |
20150306059 | METHOD FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA - Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides. | 2015-10-29 |
20150306060 | METHOD FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA - Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides. | 2015-10-29 |
20150306061 | Method For Making Bismuth Containing Liquid Pharmaceutical Suspensions - A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose. | 2015-10-29 |
20150306062 | TREATMENT AND PREVENTION OF EPITHELIAL INFECTIONS - Provided herein are sprayable copper and zinc chelate formulations for the treatment and prevention of epithelial infections in sheep, goats, horses, and cattle. More particularly, the compositions comprise micronized copper and zinc chelates suspended in a liquid, wherein the total amount of copper and zinc chelate ranges from 5 to 50 percent by weight; and less than 5% (w/v) of the chelates are dissolved. | 2015-10-29 |
20150306063 | COMPOSITION AND METHOD FOR VAGINAL THERAPY - Provided are a composition and method for vaginal therapy. The composition includes a delivery compound and a pharmaceutically active agent dispersed in the delivery compound. The pharmaceutically active agent includes a centrally acting muscle relaxant. The method for vaginal therapy includes preparing a composition including a pharmaceutically active agent dispersed in a delivery compound, and administering the composition intravaginally. The pharmaceutically active agent includes a muscle relaxant. Another method includes administering the composition extravaginally and then administering the composition intravaginally. | 2015-10-29 |
20150306064 | Wound Care Products with Peracid Compositions - Methods have been developed for incorporation of a peracid compound into or on wound application matrices, such as bandages or dressings, and other matrices which will favorably impact wound healing and help eliminate microbial infection. The peracid compound comprises a base compound that is metabolically pertinent to wound healing, the oxidized form of the base compound (a peracid), and an appropriate oxidizer, such as hydrogen peroxide. In addition, other excipients with wound healing potential, such as esters of the base compound, may be added to the peracid compound. The combination peracid-wound application matrices can be used to disinfect and heal various wound types with designed time release of the peracid compound. | 2015-10-29 |
20150306065 | A Combination of Adrenaline with an Antidepressant for Use in the Treatment of Shocks - The present invention concerns a novel combination of adrenalin with an antidepressant and its use as a pharmaceutical composition for the treatment of shocks. The pharmaceutical composition is to be administered by injection. | 2015-10-29 |
20150306066 | TREATMENT OF HUMAN CYTOMEGALOVIRUS BY MODULATING WNT - The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for treating human cytomegalovirus using Wnt pathway modulators. In a specific embodiment, a method for treating human cytomegalovirus (HCMV) in a patient in need thereof comprises administering an effective amount of Wnt pathway modulator. | 2015-10-29 |
20150306067 | SMALL MOLECULE ANTAGONISTS OF BACTERIAL QUORUM-SENSING RECEPTORS - A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote | 2015-10-29 |
20150306068 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Aspects of the invention pertain to chemical compounds, therapeutic compositions, and methods for treating neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. | 2015-10-29 |
20150306069 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS - The present invention concerns methods and compositions involving inhibitors and of RAD51, a protein involved in homologous recombination. In some embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation. | 2015-10-29 |
20150306070 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA - The present invention is related to a compound of formula (I): a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of leukemia, wherein X is selected from the group consisting of N—R | 2015-10-29 |
20150306071 | Carbapenem Antibacterials with Gram-Negative Activity - The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. | 2015-10-29 |
20150306072 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN - The invention relates to a composition comprising melatonin, a metabolite or derivative thereof and coenzyme Q10 and to use thereof for the production of a pharmaceutical or cosmetic composition for the treatment of the skin, said composition potentiating the movement of both molecules into the mitochondrion and facilitating percutaneous absorption, in which both the melatonin and the CoQ10 can reach all of the strata of the skin. | 2015-10-29 |
20150306073 | THIOREDOXIN PROTEIN INHIBITORS AND USES THEREOF - A method of treating a fungal infection in a subject including administering to the subject a therapeutically effective amount of a thioredoxin protein inhibitor to treat the fungal infection in the subject. | 2015-10-29 |
20150306074 | FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS - Compounds of formula I and their metabolites are potent mediators of an inflammatory response: | 2015-10-29 |
20150306075 | COMPOSITIONS AND METHODS OF INHIBITING METALLO-B-LACTAMASES - A method of treating a bacterial infection in a subject in need thereof includes administering to the subject therapeutically effective amounts of at least one β-lactam antibiotic and at least one bisthiazolidine metallo-β-lactamase inihibitor. | 2015-10-29 |
20150306076 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 2015-10-29 |
20150306077 | Novel Compositions and Methods for Treating Cancer - Provided herein are methods and compositions inter alia for treating diseases, including hyperproliferative diseases, migraine headaches, and depression. | 2015-10-29 |
20150306078 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF - The present invention provides compounds having the general structural formula (I) | 2015-10-29 |
20150306079 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - Combinations comprising (a) a PDE4 Inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azonlablcyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases. | 2015-10-29 |
20150306080 | METHODS FOR TREATMENT OF MELANOMA - Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma. | 2015-10-29 |
20150306081 | Chemotherapy for Drug-Resistant Cancer Cells - The present invention relates to new treatments of multidrug resistant disorders, particularly cancers. There is provided a method of treating a cancer including administering an effective amount of a semicarbazone or hydrazone compound to a patient that has cancer, the cancer including a cancerous cell that includes an active efflux mechanism; wherein the compound is a substrate of the active efflux mechanism and the compound is able to form a chelation complex with a metal species in the cancerous cell, the chelation complex being cytotoxic to the cancerous cell. | 2015-10-29 |
20150306082 | SOLENOPSIN AND DERIVATIVES, THERAPEUTIC COMPOSITIONS, AND METHODS RELATED THERETO - This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula: | 2015-10-29 |
20150306083 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention provides chromium compounds, specifically chromium dinicocysteinate, which possess the ability to improve insulin sensitization, glucose tolerance, bioavailability, efficacy, and safety, and methods for their use. | 2015-10-29 |
20150306084 | ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION - The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension. | 2015-10-29 |
20150306085 | CSF-1R INHIBITORS FOR TREATMENT OF BRAIN TUMORS - The present invention provides a compound of formula I; | 2015-10-29 |
20150306086 | MODULATING CERTAIN TYROSINE KINASES - The present invention provides therapeutic and diagnostic modalities relevant to treating disorders associated with tyrosine kinase activity. | 2015-10-29 |
20150306087 | PROPELLANT-FREE AEROSOL FORMULATION FOR INHALATION - The present invention relates to propellant-free aerosol formulations for inhalation containing ipratropium bromide and salbutamol. | 2015-10-29 |
20150306088 | LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS - This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS. | 2015-10-29 |
20150306089 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES - The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies. | 2015-10-29 |
20150306090 | ORALLY ADMINISTERED MEDICAL COMPOSITION - In order to provide the medical field with a single formulation comprising a modified release portion containing mirabegron or a pharmaceutically acceptable salt thereof and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof, (1) a single formulation having dissolution rates of both drugs similar to those of the current single drug formulations is provided, and (2) a single formulation having maximum percentages of dissolution of both drugs of 90% or more, and having a bioavailability equivalent to those of the current single drug formulations. Further, in order to provide a single formulation, (3) a single formulation having good productivity whereby failures in tabletting are reduced, and having good storage stability whereby the coloration of the immediate release portion is suppressed is provided. The pharmaceutical composition for oral administration of the present invention contains (1) a modified release portion comprising mirabegron or a pharmaceutically acceptable salt thereof, and (2) an immediate release portion comprising solifenacin or a pharmaceutically acceptable salt thereof, and calcium stearate. | 2015-10-29 |
20150306091 | ALDOSTERONE SYNTHASE INHIBITORS - This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. | 2015-10-29 |
20150306092 | TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES - Tetrahydroprotoberbine (THPB) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-THPBs of general formula (I). Enantioselective processes for preparing compounds of formula (I), and d- and l-govadine are also provided.(I) | 2015-10-29 |
20150306093 | TRANSDERMAL DELIVERY SYSTEM - The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing matrix layer on said buprenorphine-impermeable backing layer, the matrix layer comprising a) a polymer base, b) buprenorphine, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the polymer base, and C) a skin contact layer on said buprenorphine-containing matrix layer comprising a polymer-based pressure-sensitive adhesive, and optionally wherein the buprenorphine-containing self-adhesive layer structure contains said buprenorphine in an amount of less than 0.8 mg/cm2 buprenorphine base or an equimolar amount of a pharmaceutically acceptable salt thereof. | 2015-10-29 |
20150306094 | TRANS-4--N,N-DIMETHYLCARBAMOYL-CYCLOHEXYLAMINE FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA - The present invention relates to trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine (cariprazine) and pharmaceutically acceptable salts and hydrates and solvates and polymorphs thereof for use in the treatment of primary negative symptoms of schizophrenia and/or predominantly negative symptoms of schizophrenia. | 2015-10-29 |
20150306095 | An Indolinone Derivative As Tyrosine Kinase Inhibitor - The present invention relates to a compound represented by general formula (I), a method for preparing said compound, a pharmaceutical formulation containing said compound, and the use of said compound in manufacture of a medicament for treating or preventing the fibrous degeneration disease and treating the excessive proliferation disease: | 2015-10-29 |
20150306096 | 8'-HYDROXY-DIHYDROERGOTAMINE COMPOUNDS AND COMPOSITIONS - 8′-Hydroxy-Dihydroergotamine (8′-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of diseases, conditions or disorders selected from amyotrophic lateral sclerosis (ALS), Parkinson's disease, stress/anxiety, nausea, emesis, aggression, pain, neuropathic pain, sleeplessness, insomnia, restless leg syndrome and depression using the compounds, compositions, dosage forms and administration techniques disclosed herein. | 2015-10-29 |
20150306097 | HYDRAZALINE HYDORCHLORIDE PELLETS AND METHOD OF PREPARATION - Embodiments of a hydrazaline hydrochloride composition for treatment of hypoertension in humans each provide sustained release of hydralazine hydrochloride administered in the form of pellets, granules and tablets. Methods of preparation are disclosed. | 2015-10-29 |
20150306098 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA - The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvate of any of them as an active ingredient: | 2015-10-29 |
20150306099 | COMBINATION - The present invention relates to a method of treating cancer and pre-cancerous syndromes in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to a human in need thereof. | 2015-10-29 |
20150306100 | PROTEIN KINASE C INHIBITORS AND USES THEREOF - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2015-10-29 |
20150306101 | Pharmaceutical Combinations - A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. | 2015-10-29 |
20150306102 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS AKT KINASE INHIBITORS - Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals. | 2015-10-29 |
20150306103 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2015-10-29 |
20150306104 | COMBINATION THERAPY - The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof. | 2015-10-29 |
20150306105 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE - The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications. | 2015-10-29 |
20150306106 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2015-10-29 |
20150306107 | SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia - The Substituted Amine Analogs (SAA) derivative compounds and SAA complex compounds disclosed in the present invention are characterized as compositions having the functions of inhibiting disorders caused by oxidative stress, and more particularly to those SAA derivative compounds capable of inhibiting disorders caused by oxidative stress because of neurodegenerative diseases, lung diseases, oxidative stress-induced heart disease and carvenosus dysfunction. | 2015-10-29 |
20150306108 | COMPOSITIONS OF ALDH1A1 INHIBITORS AND METHODS OF USE IN TREATING CANCER - The present invention provides inhibitors of ALDH1A1 activity which have substantially no effect on either ALDH2 or ALDH3A1. Compositions and methods of use, as well as methods to treat cancer using the ALDH1A1 inhibitors, are also provided. | 2015-10-29 |
20150306109 | Compositions Comprising Nicotinic Agonists and Methods of Using Same - The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that include a nicotinic agonist (for example, nicotine) and a nicotinic acetylcholine receptor desensitization inhibitor (for example, opipramol). | 2015-10-29 |
20150306110 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION AND HYPERKERATOTIC LESIONS - A method of treating inflammation and hyperkeratotic lesions in a mammal in need thereof, by administering the following compound, a related compound, or a pharmaceutically acceptable salt thereof to the mammal: | 2015-10-29 |
20150306111 | PHARMACEUTICAL COMPOSITION COMPRISING DESLORATADINE AND PREDNISOLONE AND THEIR USE - The present invention relates to a liquid pharmaceutical composition for oral administration and its use, wherein said composition comprises: (i) a therapeutically effective amount of desloratadine or a pharmaceutically acceptable salt thereof; (ii) a therapeutically effective amount of prednisolone or a pharmaceutically acceptable salt thereof; (iii) a set of pharmaceutically acceptable excipients wherein the employed flavoring agent excipient being free of vanillin or a derivative thereof, and wherein the pH of said composition is maintained at a value in the range between 6.0 and 7.5. | 2015-10-29 |
20150306112 | Zhankuic acid A, a JAK2/3 tyrosine kinase inhibitor, and a potential therapeutic agent for hepatitis - Zhankuic acid A (ZAA) could suppress phosphorylation of JAK2 and JAK3 and signaling of downstream molecules. Moreover, ZAA could inhibit the IFN-γ/STAT1/IRF-1 pathway in vivo and in vitro. Furthermore, data show that pre-treatment with ZAA could significantly ameliorate Con A-induced hepatitis in mice. The above results strongly suggest that ZAA treatment could block JAK2 and JAK3 activation, and may be a valuable therapeutic approach for the treatment of immune cell induced inflammation. | 2015-10-29 |
20150306113 | Bismuth Containing Liquid Pharmaceutical Suspensions - A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate. | 2015-10-29 |
20150306114 | Cyclic Amines - The present invention is directed to novel cyclic amines which inhibit the P2X | 2015-10-29 |
20150306115 | PREVENTION OR TREATMENT AGENT FOR HEPATIC FIBROSIS - CBP/β-catenin inhibitor shows a superior defibrosing effect for Cre/loxP/HCV-MxCre transgenic mouse which is an animal experiment model of hepatic fibrosis, and useful as a prophylactic or therapeutic drug for hepatic fibrosis. | 2015-10-29 |
20150306116 | NOVEL ORAL FORMS OF A PHOSPHONIC ACID DERIVATIVE - Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them. | 2015-10-29 |
20150306117 | INFANT NUTRITION FOR IMPROVING FATTY ACID COMPOSITION OF BRAIN MEMBRANES - The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes. | 2015-10-29 |
20150306118 | EXTERNAL SKIN AGENT COMPRISING MODIFIED CLAY FOR PREVENTING INFLAMMATION - To provide an external skin agent that prevents onset of atopic skin inflammations and is low irritant to skin, which is characterized by including: 1) clay modified by a compound having a quaternary amino group; and 2) a polymer or copolymer that has a side chain including a structure similar to a biological component. | 2015-10-29 |
20150306119 | APPLICATION OF AMERICAN GINSENG TO ENHANCE NEUROCOGNITIVE FUNCTION - Disclosed are methods of enhancing neurocognitive function by administering of American | 2015-10-29 |
20150306120 | INHIBITING INFLAMMATION WITH MILK OLIGOSACCHARIDES - A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides. | 2015-10-29 |
20150306121 | PROCESSING OF NATURAL POLYSACCHARIDES BY SELECTED NON-PATHOGENIC MICROORGANISMS AND METHODS OF MAKING AND USING THE SAME - The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement. | 2015-10-29 |
20150306122 | APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF - In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug). | 2015-10-29 |
20150306123 | USE OF IVERMECTIN AND DERIVATIVES THEREOF - The present invention relates to the new use of antiparasitic agents, such as ivermectin, abamectin/avermectin, doramectin and so on, and the design method of the derivatives for the new use. The said compounds including macrolide abamectin/avermectin, ivermectin, doramectin and the derivatives thereof, may be used in the manufacture of a medicament for use in treating metabolic related diseases in a mammal, such as hyperglycemia, insulin resistance, hypertriglyceridemia, hypercholesterolemia, diabetes, obesity, etc, and Famesoid X receptor mediated diseases, such as cholestasia, gallstone, non alcohol fatty liver disease, atherosclerosis, inflammation, cancer, etc. | 2015-10-29 |
20150306124 | TOPICAL APPLICATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS/AFFLICTIONS - Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin. | 2015-10-29 |
20150306125 | AGENT FOR PREVENTING OR IMPROVING DECLINE IN BRAIN FUNCTION - An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentration, decreased attention, decreased judgment ability, depression, and decreased exercise performance caused thereby. According to the present invention, an agent for protecting brain neuronal cells, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients as well as an agent for preventing or improving decline in brain function, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients is provided. | 2015-10-29 |
20150306126 | SOLID ORAL COMPOSITIONS BASED ON S-ADENOSYL METHIONINE AND/OR NADH AND PROCESS FOR OBTAINING THEM - This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. | 2015-10-29 |
20150306127 | MIRNAS AS NOVEL THERAPEUTIC ADJUVANTS AND BIOMARKERS FOR THE PROGNOSIS AND TREATMENT OF DRUG RESISTANT BREAST CANCERS - Disclosed are methods and compositions for using microRNA (miRNA) for treating cancer. The methods and compositions include hsa-miR-204 and homologs of hsa-miR-204. | 2015-10-29 |
20150306128 | COBALAMINS TO HELP MAINTAIN A NORMAL BODY WEIGHT AND A HEALTHY BODY MASS INDEX (BMI) IN UNDERWEIGHT, OVERWEIGHT AND OBESE HUMANS - The current invention discloses novel uses of orally ingested cobalamins for the maintenance of a healthy and normal body weight and body mass index (BMI). Cobalamins support mitochondrial conversion of carbohydrates into chemical energy called ATP. Cells in the body, especially energy-hungry muscle and brain cells, use ATP as an energy source for many types of cellular functions. Simply put, cobalamins are the natural nutrients needed for cellular metabolism and the burning of calories. In a phase III, placebo-controlled, nutritional study with a total of 1,551 human test subjects, on average those obese people who took cobalamins lost weight and BMI, while those obese people who took placebo gained weight and BMI. | 2015-10-29 |
20150306129 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OBESITY - A pharmaceutical or dietary composition for oral administration based on activated cellulose is described. The composition is useful in the treatment of obese or overweight subjects and of subjects suffering from hyperglycaemia or from hyperlipidaemia. | 2015-10-29 |